Costunolide(Synonyms: 木香烃内酯; (+)-Costunolide; Costus lactone)

上海金畔生物科技有限公司提供天然产物萜类及其苷类Terpenoids and Glycosides。

Costunolide (Synonyms: 木香烃内酯; (+)-Costunolide; Costus lactone) 纯度: 99.97%

Costunolide ((+)-Costunolide) 是一种天然的倍半萜内酯,它具有抗氧化、抗炎、抗过敏、骨重塑、神经保护、促进毛发生长、抗癌和抗糖尿病的特性。Costunolide 可诱导乳腺癌细胞周期阻滞和凋亡 (apoptosis)。

Costunolide(Synonyms: 木香烃内酯; (+)-Costunolide;  Costus lactone)

Costunolide Chemical Structure

CAS No. : 553-21-9

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in DMSO ¥614 In-stock
5 mg ¥558 In-stock
10 mg ¥837 In-stock
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

Costunolide 相关产品

相关化合物库:

  • Covalent Screening Library Plus
  • Natural Product Library Plus
  • Bioactive Compound Library Plus
  • Apoptosis Compound Library
  • Metabolism/Protease Compound Library
  • Natural Product Library
  • Anti-Cancer Compound Library
  • Human Endogenous Metabolite Compound Library
  • Covalent Screening Library
  • Diabetes Related Compound Library
  • Terpenoids Library
  • Traditional Chinese Medicine Monomer Library
  • FDA Approved & Pharmacopeial Drug Library
  • Neuroprotective Compound Library
  • Anti-Breast Cancer Compound Library
  • Food-Sourced Compound Library

生物活性

Costunolide ((+)-Costunolide) is a naturally occurring sesquiterpene lactone, with antioxidative, anti-inflammatory, antiallergic, bone remodeling, neuroprotective, hair growth promoting, anticancer, and antidiabetic properties. Costunolide can induce cell cycle arrest and apoptosis on breast cancer cells[1][2][3].

IC50 & Target

Human Endogenous Metabolite

 

体外研究
(In Vitro)

Costunolide inhibits the colony formation, migrative and invasive abilities of the H1299 cells in a dose or time dependent manner[2].
Costunolide (6.7-215.2 μM; 24 hours) inhibits the viability of H1299 cells in a dose-dependent manner, with an IC50 of 23.93 µM[2].
Costunolide (12.0-48.0 µM; 48 hours) induces apoptosis in H1299 cells[2].
Costunolide (12-48.0 µM; 6-12 hours) regulates metastasis- and proliferation-associated mRNA expression[2].
Costunolide regulates epithelial-to-mesenchymal transition (EMT)-associated protein expression[2].
Costunolide regulates c-Myc mediated apoptosis signaling and 14-3-3-mediated signaling pathways in breast cancer cells[3].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[2]

Cell Line: H1299 cells
Concentration: 6.7 μM, 13.5 μM, 26.9 μM, 107.6 μM, 215.2 μM
Incubation Time: 24 hours
Result: Inhibited the viability of H1299 cells (MTT assay).

Apoptosis Analysis[2]

Cell Line: H1299 cells
Concentration: 0 µM, 12.0 µM, 24.0 µM, 48.0 µM
Incubation Time: 48 hours
Result: Significantly promoted apoptosis at 24.0 µM and 48.0 µM.

RT-PCR[2]

Cell Line: H1299 cells
Concentration: 0 µM, 12.0 µM, 24.0 µM, 48.0 µM
Incubation Time: 6 hours, 12 hours
Result: Regulated the metastasis- and proliferation-associated mRNA levels in a dose-dependent manner.

Western Blot Analysis[2]

Cell Line: H1299 cells
Concentration: 0 µM, 12.0 µM, 24.0 µM, 48.0 µM
Incubation Time: 48 hours
Result: Significantly inhibited the EMT of H1299 cells.

体内研究
(In Vivo)

Costunolide (20 mg/kg; i.p; daily; for 30 days) inhibits breast cancer through c-Myc/p53 and AKT/14-3-3 pathway[3].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: 4 weeks old female BALB/c nude mice, MDA-MB-231 cells xenograft mouse models[3]
Dosage: 20 mg/kg
Administration: Intraperitoneal injection, daily, for 30 days
Result: Reduced the expression levels of c-Myc and p-AKT and elevated the expression levels of p53 and p-14-3-3.

分子量

232.32

Formula

C15H20O2

CAS 号

553-21-9

中文名称

木香烃内酯;木烃香内酯

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

-20°C, sealed storage, away from moisture and light

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

溶解性数据
In Vitro: 

DMSO : ≥ 49 mg/mL (210.92 mM)

* “≥” means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 4.3044 mL 21.5220 mL 43.0441 mL
5 mM 0.8609 mL 4.3044 mL 8.6088 mL
10 mM 0.4304 mL 2.1522 mL 4.3044 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.08 mg/mL (8.95 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (8.95 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.08 mg/mL (8.95 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (8.95 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.08 mg/mL (8.95 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (8.95 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 Shanghai Jinpan Biotech Co Ltd 网站选购。
参考文献
  • [1]. Dae Yong Kim, et al. Costunolide-A Bioactive Sesquiterpene Lactone with Diverse Therapeutic Potential. Int J Mol Sci. 2019 Jun; 20(12): 2926.

    [2]. Minyan Wei, et al. Costunolide induces apoptosis and inhibits migration and invasion in H1299 lung cancer cells. Oncol Rep. 2020 Jun;43(6):1986-1994.

    [3]. Zhangxiao Peng, et al. Costunolide and dehydrocostuslactone combination treatment inhibit breast cancer by inducing cell cycle arrest and apoptosis through c-Myc/p53 and AKT/14-3-3 pathway.Sci Rep. 2017; 7: 41254.